|Title||Mechanisms of iPS cell generation and beyond.|
|Publication Type||Journal Article|
|Year of Publication||2017|
|Journal||Keio J Med|
|Keywords||Adipocytes, Animals, B-Lymphocytes, Cell Transdifferentiation, Cellular Reprogramming, Fibroblasts, Gene Expression Regulation, Humans, Induced Pluripotent Stem Cells, Kruppel-Like Transcription Factors, Macrophages, Mice, Myoblasts, Neurons, Octamer Transcription Factor-3, Proto-Oncogene Proteins c-myc, Smad3 Protein, SOXB1 Transcription Factors|
The generation of induced pluripotent stem cells (iPSCs) achieved by overexpression of Oct4, Sox2, Klf4 and c-Myc, transformed our classical views of the cellular epigenetic landscape and delivered a new concept for cell and tissue engineering. In addition to iPSCs, several other cell types have also been generated by master transcription factor (TF)-mediated transdifferentiation. However, the critical molecular mechanisms amongst diverse cellular identity changes are not well understood. Through the investigation of reprogramming mechanisms, we recently revealed that over-expression of constitutive active Smad3 boosted not only iPSC generation, but also 3 other master TF-mediated conversions, from B cells to macrophages, myoblasts to adipocytes, and human fibroblasts to neurons. This demonstrated that there were common mechanisms underlying different master TF-mediated cell conversions. To illuminate such mechanisms further, we have recently performed CRISPR/Cas9-mediated genome-wide knockout screening during reprogramming with a lentiviral gRNA library containing 90,000 gRNAs. This screening provided us with ~15 novel reprogramming roadblock genes as well as ~20 candidate genes essential for the reprogramming process but not for ES cell self-renewal. This data set will be a valuable resource to further understand how overexpression of master TFs alters cellular identity, and to achieve more faithful, efficient cell conversions for regenerative medicine.(Presented at the 1934th Meeting, March 17, 2017).
|Alternate Journal||Keio J Med|